<DOC>
	<DOCNO>NCT01445041</DOCNO>
	<brief_summary>Further study detail provide Duke University : Purpose : To evaluate feasibility safety collect infuse autologous umbilical cord blood ( UCB ) newborn infant hypoplastic leave heart syndrome ( HLHS ) . Study Rationale Hypotheses : The major goal study determine whether infusion autologous UCB cell neonates hypoplastic leave heart syndrome feasible safe . The rationale study potential benefit UCB base upon follow hypothesis : 1 . Infants HLHS significant neural injury evidence prenatal early antenatal brain MRI finding infusion UCB cell may lessen neural injury . Although exact mechanism unknown , UCB cell infusion may ameliorate neural injury via paracrine anti-inflammatory effect enhance post injury repair may promote endogenous functional compensation cortical area result significant clinical improvement . 2 . UCB cell may also enhance cardiac function , minimize scar formation , reverse detrimental remodel cardiac injury .</brief_summary>
	<brief_title>Safety Feasibility Study Umbilical Cord Blood Cells Infants With Hypoplastic Left Heart Syndrome</brief_title>
	<detailed_description>The purpose pilot study evaluate safety feasibility infusion autologous ( patient 's ) umbilical cord blood cell neonates hypoplastic leave heart syndrome . This prospective , randomized Phase I trial design assess safety feasibility autologous UCB reinfusion neonates Hypoplastic Left Heart Syndrome ( HLHS ) . Neonates identify prenatally cardiac lesion consistent HLHS refer Duke Cardiology evaluation . If meet inclusion criterion , UCB collect time delivery process ( red blood cell- volume-reduced ) reinfusion . All enrol infant receive dose fresh UCB cell pre-operatively Â½ enrol infant randomly select receive second dose frozen thaw UCB cell stage 1 palliation ( 5-35 day post-operatively ) third dose frozen thaw UCB cell 2 4 week 2nd infusion . Neurodevelopmental outcome measure assess 1 month discharge , 4-6 month old 12 month . The result MRI 's echocardiogram obtain per clinical routine analyze describe study report .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
	<criteria>Infants &gt; 35 week gestational age . Diagnosis : Hypoplastic Left Heart Syndrome . Autologous umbilical cord blood available minimum total nucleate cell dose 1 x 10e7 cells/kg . Parental Consent . Chromosomal anomaly identify time infusion . Chromosomal anomaly congenital anomaly would prohibit clinician initiate surgical repair congenital heart defect . Infant determine clinical staff nonviable receive aggressive care . ( No member study team involve determine viability neonate . ) Autologous umbilical cord blood unit follow : Total nuclear cell count &lt; 1 x 10e7 . Positive maternal infectious serology ( except CMV ) . Evidence infectious contamination cord blood unit . Evidence genetic disease . Unable obtain parental consent . Mother &lt; 18 year old .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypoplastic Left Heart Syndrome</keyword>
	<keyword>Autologous Umbilical Cord Blood</keyword>
	<keyword>Newborn Infants</keyword>
</DOC>